Bank of America Securities analyst Tazeen Ahmad has reiterated their bullish stance on VRTX stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tazeen Ahmad has given his Buy rating due to a combination of factors tied to Vertex’s strong clinical and commercial outlook. The pivotal IgAN study for pove’ showed nearly a 50% placebo-adjusted drop in proteinuria with statistically robust results, alongside a convenient low-dose, monthly autoinjector regimen that aligns with physicians’ preferred treatment profile and should stand out even in a competitive market.
Ahmad also highlights a clean safety profile without concerning infection or hypoIgG signals, despite extensive exposure and high use of background standard therapies, which reinforces confidence in broader nephrology opportunities. Together with sizable risk-adjusted peak sales potential, validation of the Alpine acquisition, and a higher price objective versus the current share price, these elements underpin the view that VRTX remains a compelling large-cap biotech opportunity warranting a Buy rating.
In another report released today, Citi also maintained a Buy rating on the stock with a $585.00 price target.
VRTX’s price has also changed moderately for the past six months – from $396.480 to $460.870, which is a 16.24% increase.